An evaluation of arbaprostil at multiple doses for the treatment of acute duodenal ulcer: a randomized double-blind placebo-controlled international trial.

Abstract

Six hundred and thirty patients were enrolled in a randomized double-blind placebo-controlled trial evaluating two arbaprostil dosages (25 micrograms and 50 micrograms) qid for 4 wk for the treatment of acute duodenal ulcers. The healing rates in the placebo, 25-micrograms, and 50-micrograms treatment groups were 39%, 51%, and 60%, respectively. Smoking was found to adversely affect the healing rates in all the treatment groups. Pain severity was less with either arbaprostil treatment. The only side effect found was diarrhea: 10%, 14%, and 32% in the placebo, 25-micrograms, and 50-micrograms treatment groups, respectively. Severe diarrhea occurred in 1% of those patients who received the 50-micrograms dosage regimen, but in none of the other two groups. Arbaprostil at these two dosage levels, when given for 4 wk, appears to be a safe and efficacious agent for the treatment of acute duodenal ulcers.

• Authors: A R Euler, J Krawiec, H Odes, T Gilat, L Garcia, D Rachmilewitz, A Gabryelewicz, K Gibinski, D Bass, L Barbara
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 85 Issue 2 Pg. 145-9 (Feb 1990) ISSN: 0002-9270 [Print] United States
• PMID: 2405642 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Capsules
• Placebos
• Prostaglandins E, Synthetic
• Arbaprostil

Topics

• Acute Disease
• Arbaprostil (administration & dosage, adverse effects)
• Capsules
• Double-Blind Method
• Duodenal Ulcer (blood, diagnosis, drug therapy)
• Duodenoscopy
• Female
• Humans
• Male
• Multicenter Studies as Topic
• Placebos
• Prostaglandins E, Synthetic (administration & dosage)
• Randomized Controlled Trials as Topic
• Time Factors
• Wound Healing (drug effects)